Pharma distribution directory 2026

    Pharmaceutical Distributors in China

    China’s pharmaceutical wholesale is a four-house plus province story: Sinopharm, Shanghai Pharmaceuticals, China Resources Pharmaceutical and Jointown move most of the documented volume, while provincial volume-based procurement decides the hospital pack before a depot even opens the carton.

    The National Medical Products Administration licenses manufacturers, importers and wholesale enterprises; provincial medical products administrations inspect the warehouses that hold the goods. The two-invoice rule collapsed the old multi-tier trader stack, so a principal now invoices a national or provincial wholesaler once and that wholesaler invoices the hospital or retail pharmacy once. Volume-based procurement run by the National Healthcare Security Administration and provincial alliances has compressed hospital prices and pushed distributors into a logistics-and-credit role rather than a margin-on-spread role. Community pharmacies — Yifeng, Dashenlin, LBX, Yixintang and thousands of regional banners — buy centrally and increasingly bypass the secondary wholesaler. BioNixus treats the four listed groups, the provincial VBP desk and the retail banners as separate accounts, because a Shanghai hospital win does not predict a Chengdu chemist facing.

    Updated September 2026 · National Medical Products Administration (NMPA) — licensed drug manufacturers, importers and wholesale enterprises as of September 2026 · 14 named accounts

    Request a proposal for ChinaBrowse the 14 companies

    4

    National groups that still dominate documented hospital and retail wholesale

    VBP

    Provincial and national volume-based procurement setting hospital pack prices

    Two invoices

    Manufacturer-to-wholesaler then wholesaler-to-provider — the legal path

    NMPA

    Central licence; provincial bureaus inspect the actual godown

    Named accounts

    Top pharmaceutical distributors in China

    Public, well-known names BioNixus studies at account and SKU level. This is an editorial snapshot, not an endorsement or a market-share ranking. Cross-checked against National Medical Products Administration (NMPA) — licensed drug manufacturers, importers and wholesale enterprises (as of 2026-09-05).
    #CompanyHQ
    01Sinopharm GroupShanghai / Beijing
    02Shanghai Pharmaceuticals (SPH)Shanghai
    03China Resources PharmaceuticalHong Kong / Beijing
    04Jointown Pharmaceutical GroupWuhan
    05National Healthcare Security Administration — VBP deskBeijing
    06National Medical Products Administration (NMPA)Beijing
    07Provincial medical products administrationsProvincial capitals
    08Yifeng PharmacyChangsha
    09Dashenlin Pharmaceutical GroupGuangzhou
    10LBX PharmacyShanghai
    11YixintangKunming
    12Sinopharm Accend (specialty / vaccines)Shanghai
    13SF Express / JD Logistics life-science lanesShenzhen / Beijing
    14County hospital pharmacy departments (aggregated)County seats

    Primary research

    These are the distributors and wholesalers we map in China

    Choosing or auditing a distribution partner in China? BioNixus runs distributor due-diligence interviews, channel-share estimates and pharmacy-level availability checks. Proposal ready within 48 hours of a brief.

    Planning research in China?

    Primary research, market access & HEOR. Proposals within 48 hours.

    Top market research companies in China (2026)

    How the market is structured

    Two invoices, VBP awards and four listed books

    A foreign innovator or a domestic generic house sells to Sinopharm, SPH, CR Pharmaceutical or Jointown (or a provincial specialist) under a two-invoice contract. That wholesaler then invoices a Class III hospital, a county hospital, a community health centre or a retail banner. Secondary traders still exist in some provinces for retail fill-in, but they are legally thinner than a decade ago and a compliance team will not want them on an innovator file. VBP awards are won at the manufacturer desk; the distributor’s job is to deliver the awarded pack into the hospital warehouse on the province’s timetable and to carry the receivables. Retail is a different P&L: listed chemist groups run their own DC networks in Guangdong, Jiangsu and Sichuan, and they bargain as retailers, not as hospital logistics. Cold-chain biologics concentrate in Shanghai, Beijing, Guangzhou and Suzhou bonded zones, with the same four groups plus specialist 3PLs holding validated rooms. County hospitals and township health centres still depend on provincial Sinopharm or CR branches that a Beijing headquarters slide will under-name. Write the province, the VBP batch and the outlet type on the brief. “China distribution” without those three is a press release.

    Local

    SPH and Jointown as the large non-pure-SOE national books, plus listed chemist banners that self-distribute. They invoice hospitals or stores under two-invoice rules and live on credit days as much as on spread.

    • Shanghai Pharmaceuticals (SPH)
    • Jointown Pharmaceutical Group

    Multinational

    Foreign principals almost never wholesale in China. International 3PLs and express life-science lanes store and move; the importer of record is usually the local affiliate.

    Regional

    Greater China trading groups that treat the mainland beside Hong Kong or Taiwan, typically on selected imported specialty and consumer-health SKUs rather than VBP generics.

    Wholesalers, importers & 3PL

    Sinopharm, CR Pharmaceutical, the NHSA VBP desk, provincial MPAs and county hospital pharmacies: the state-linked path that still decides most hospital units.

    • Sinopharm Group
    • China Resources Pharmaceutical
    • National Healthcare Security Administration — VBP desk
    • National Medical Products Administration (NMPA)
    • Provincial medical products administrations
    • Yifeng Pharmacy
    • Dashenlin Pharmaceutical Group
    • LBX Pharmacy
    • Yixintang
    • Sinopharm Accend (specialty / vaccines)
    • SF Express / JD Logistics life-science lanes
    • County hospital pharmacy departments (aggregated)

    What is moving

    What is moving pharma distribution in China

    VBP batches rewriting hospital demand

    Each national or provincial batch resets which pack the four wholesalers must deliver. Distributor share follows the award, so a pre-VBP coverage map is a historical document.

    Two-invoice enforcement

    Secondary traders lost legal room. Principals that still design a three-tier cascade will fail compliance reviews and still not reach the hospital warehouse faster.

    Retail banners building their own DCs

    Yifeng, Dashenlin, LBX and Yixintang buy as retailers. Hospital wholesalers lose that slice unless they win the banner’s inbound contract, which is a different tender.

    County and community health volume

    VBP and hierarchical diagnosis push volume out of Tier-1 Class III hospitals. Provincial Sinopharm and Jointown branches that can serve county seats pick up the work Beijing slides forget.

    BioNixus fieldwork

    How BioNixus studies pharmaceutical distributors in China

    The accounts above are the ones our field teams and analysts work with. What a brand team typically commissions from us in China:
    • Hospital pharmacy purchase-record cuts in one coastal and one inland province, split by Class III versus county, naming which of the four groups invoiced the pack.
    • VBP award-to-warehouse tracking: days from published winner to first hospital receipt, and which provincial subsidiary actually delivered.
    • Retail-banner DC interviews at two listed chemist groups on inbound terms versus hospital two-invoice contracts on the same molecule.
    • Cold-room walk-throughs in Shanghai and Guangzhou bonded zones comparing Sinopharm specialty units with express 3PL rooms.

    Healthcare market research in China

    Questions

    Frequently Asked Questions

    Can a foreign company appoint a single China-wide exclusive wholesaler?

    It can name a lead, but hospital and retail execution still runs through provincial subsidiaries of Sinopharm, SPH, CR or Jointown. Exclusive paper in Shanghai will not stock a Zhengzhou county hospital.

    What did volume-based procurement change for distributors?

    Prices and winners are set at the manufacturer–payer desk. Distributors deliver the awarded pack and carry hospital receivables. Margin-on-spread wholesale on VBP molecules is largely gone.

    Who are the four national pharmaceutical wholesalers?

    Sinopharm, Shanghai Pharmaceuticals, China Resources Pharmaceutical and Jointown. Provincial specialists and chemist-banner DCs sit around them; they do not replace them on hospital files.

    Do retail pharmacy chains still buy from the national wholesalers?

    Sometimes on inbound logistics, often not on listing. Listed banners run their own DCs and bargain as retailers. Design hospital and retail as two studies.

    What does BioNixus field on Chinese pharmaceutical distribution?

    Provincial subsidiary mapping for the four groups, VBP award-to-delivery tracking in two provinces, retail-banner DC interviews, and hospital-pharmacy purchase cuts that separate Class III from county outlets.

    Is this a ranking of Chinese wholesalers?

    No. The page groups state-linked books, private national wholesale, VBP and licensing desks, chemist banners and 3PLs so a launch team can see which desk owns the next action.

    Sources

    Data sources & methodology

    This directory aggregates publicly available company and channel facts — filings, brand sites, and BioNixus fieldwork in China. It is an editorial snapshot of the accounts we study, not a share ranking and not a substitute for NielsenIQ, IQVIA, or another syndicated feed.

    Primary register: National Medical Products Administration (NMPA) — licensed drug manufacturers, importers and wholesale enterprises, consulted 2026-09-05. Company classification (Local / MNC / Regional / wholesalers, importers & 3pl) reflects ownership and role in China, not size.

    • NMPA and provincial MPA wholesale licensing notices, 2024–2026
    • NHSA VBP batch announcements and provincial alliance award lists, 2024–2026
    • Hong Kong and A-share filings of Sinopharm, SPH, CR Pharmaceutical and Jointown, 2024–2025
    • BioNixus China hospital-pharmacy and distributor fieldwork, 2023–2026

    BioNixus sells account-level and SKU-level primary research that complements those subscriptions. For a scoped proposal, contact the team or use the form below. Email admin@bionixus.com.

    48-hour proposal

    Need distributor and channel data in China?

    Coverage, credit terms, cold-chain capability and share of pharmacy purchases by wholesaler — from the pharmacies and hospitals themselves, not a directory.

    Planning research in China?

    Primary research, market access & HEOR. Proposals within 48 hours.